Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study-Reference-Cited by-同舟云学术

Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study

Published:2021-03 Issue:3 Volume:3 Page:e204-e213
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Tehlirian Christopher,Peeva Elena,Kieras Elizabeth,Scaramozza Matthew,Roberts Erika S,Singh Ravi Shankar P,Pradhan Vivek,Banerjee Anindita,Garcet Sandra,Xi Li,Gale Jeremy D,Vincent Michael S,Krueger James

Funder

Pfizer

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference28 articles.

1. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines;Fitch;Curr Rheumatol Rep,2007

2. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011;Armstrong;PLoS One,2012

3. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?;Langley;J Eur Acad Dermatol Venereol,2012

4. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy;Norlin;J Dermatolog Treat,2017

5. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION);Saurat;Br J Dermatol,2008

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition;Journal of Clinical Medicine;2024-05-24

2. Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors;JAMA Dermatology;2024-03-01

3. New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis;Pharmaceutics;2024-02-06

4. A comprehensive review of discovery and development of drugs discovered from 2020–2022;Saudi Pharmaceutical Journal;2024-01

5. Psoriasis: a focus on upcoming oral formulations;Expert Opinion on Investigational Drugs;2023-07-03